HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Vaccine
; 26(52): 6844-51, 2008 Dec 09.
Article
en En
| MEDLINE
| ID: mdl-18930097
ABSTRACT
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por Papillomavirus
/
Vacunas contra Papillomavirus
/
Anticuerpos Antivirales
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
Idioma:
En
Año:
2008
Tipo del documento:
Article